Whole Foods (NASDAQ:WFM): Investor concerns over the company’s FY13 guidance are overdone, according to Cantor, which expects the grocery store chain to report higher than expected Q2 EPS. It keeps a Buy rating on the shares.
Fiserv (NASDAQ:FISV): Argus says that despite the lower than expected Q1 EPS, the company’s valuation remains attractive and should benefit from accelerating IT outsourcing by financial institutions. It keeps a Buy rating and a $105 price target on the shares.
Weatherford (NYSE:WFT): Sterne Agee believes that the company’s reiteration of its 2013 cash flow guidance displays capital discipline, and notes that the company is also increasing its ficus on matters in which it has expertise. It maintains a Buy rating on the stock.
Biogen (NASDAQ:BIIB): Deutsche Bank believes that IMS scripts indicate that Biogen’s multiple sclerosis treatment Tecfidera is on track to top consensus expectations by $400 million in 2013, and if scripts stabilize at current levels, Tecfidera sales could come in at a healthy $651 million for 2013, above the projections of $248 million. It maintains a Buy rating on the shares, with a $240 price target.
Investing Insights: Could Coca-Cola Be Facing a Slowdown?